Poly Medicure Limited
POLYMED · General/Diversified · NSE
₹1,418
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for POLYMED yet. Reason: Data Limited.
Updated 6h ago
YieldIQ Score
—
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
30%
ROE
12.2%
Debt/Equity
0.07
WACC
9.8%
Market Cap
₹14,368 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.6%
Return on capital employed
EV / EBITDA
24.1×
Enterprise multiple
Debt / EBITDA
0.4×
Leverage vs earnings
Interest Coverage
40.5×
EBIT covers interest
Current Ratio
5.18×
Short-term liquidity
Asset Turnover
0.54×
Revenue per ₹ of assets
Revenue CAGR (3Y)
9.0%
3-year revenue growth
Revenue CAGR (5Y)
14.0%
5-year revenue growth
Ratio Trends
POLYMED · last 8 annual periods
ROE
12.2%
ROCE
18.6%
Operating Margin
—
Debt / Equity
0.07×
PE
164.2×
EV / EBITDA
32.2×
Historical Financials
POLYMED · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹917 Cr | ₹1109 Cr | ₹1366 Cr | ₹1670 Cr | ₹1875 Cr | +19.6% |
| EBITDA | ₹253 Cr | ₹303 Cr | ₹419 Cr | ₹548 Cr | ₹561 Cr | +22.1% |
| EBIT | ₹197 Cr | ₹244 Cr | ₹353 Cr | — | — | +15.7% |
| PAT | ₹147 Cr | ₹179 Cr | ₹258 Cr | ₹339 Cr | ₹331 Cr | +22.6% |
| EPS (diluted) | ₹15.27 | ₹18.67 | ₹26.90 | — | — | +15.2% |
| CFO | ₹123 Cr | ₹191 Cr | ₹266 Cr | ₹233 Cr | ₹246 Cr | +18.9% |
| CapEx | ₹-156 Cr | ₹-239 Cr | ₹-277 Cr | ₹-331 Cr | ₹-308 Cr | — |
| FCF | ₹-32.1 Cr | ₹-48.2 Cr | ₹-10.9 Cr | ₹-98.0 Cr | ₹-62.0 Cr | — |
| Total Assets | ₹1377 Cr | ₹1577 Cr | ₹1859 Cr | ₹3192 Cr | ₹3919 Cr | +29.9% |
| Total Debt | ₹127 Cr | ₹149 Cr | ₹174 Cr | ₹180 Cr | ₹354 Cr | +29.2% |
| Shareholders' Equity | ₹1087 Cr | ₹1242 Cr | ₹1470 Cr | ₹2766 Cr | ₹3106 Cr | +30.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
POLYMED vs 1 closest peer by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
AGARWALEYE Dr. Agarwal's Health Care Limited | -90.0% | 20 | Data Limited | 6.6% | — |
Click a ticker to view its fair-value analysis.
Dividend History
12 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹14.50/sh
Last payout
2025-09-18
₹3.50
Peak payout
₹3.50
Trailing yield
0.25%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of POLYMED →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for POLYMED →
Compare
Head-to-head with peers
Compare POLYMED side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse POLYMEDNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.